Connor Clark & Lunn Investment Management Ltd. Makes New $1.96 Million Investment in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Connor Clark & Lunn Investment Management Ltd. acquired a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 40,948 shares of the biopharmaceutical company's stock, valued at approximately $1,958,000.

A number of other hedge funds and other institutional investors have also modified their holdings of HALO. Heck Capital Advisors LLC acquired a new stake in shares of Halozyme Therapeutics in the 4th quarter valued at $29,000. Smartleaf Asset Management LLC grew its position in shares of Halozyme Therapeutics by 29.2% in the 4th quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company's stock valued at $42,000 after buying an additional 197 shares during the last quarter. Venturi Wealth Management LLC purchased a new position in shares of Halozyme Therapeutics in the 4th quarter valued at $69,000. Parkside Financial Bank & Trust grew its position in shares of Halozyme Therapeutics by 21.8% in the 4th quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company's stock valued at $86,000 after buying an additional 322 shares during the last quarter. Finally, Centaurus Financial Inc. purchased a new position in shares of Halozyme Therapeutics in the 3rd quarter valued at $127,000. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Halozyme Therapeutics Stock Performance

Halozyme Therapeutics stock traded up $0.84 during midday trading on Friday, hitting $65.16. 4,001,023 shares of the company's stock were exchanged, compared to its average volume of 1,327,557. Halozyme Therapeutics, Inc. has a 12-month low of $37.73 and a 12-month high of $65.53. The stock has a market cap of $8.02 billion, a price-to-earnings ratio of 19.00, a price-to-earnings-growth ratio of 0.42 and a beta of 1.32. The company has a debt-to-equity ratio of 4.14, a quick ratio of 9.15 and a current ratio of 7.80. The firm's 50 day simple moving average is $58.20 and its 200 day simple moving average is $54.76.

Remove Ads

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last released its earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 EPS for the quarter, topping the consensus estimate of $1.17 by $0.02. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. The company had revenue of $298.01 million during the quarter, compared to analysts' expectations of $285.74 million. Equities research analysts predict that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Insider Transactions at Halozyme Therapeutics

In related news, Director Jeffrey William Henderson sold 5,000 shares of the firm's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $58.69, for a total value of $293,450.00. Following the completion of the sale, the director now owns 33,611 shares in the company, valued at $1,972,629.59. This trade represents a 12.95 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Michael J. Labarre sold 10,000 shares of the firm's stock in a transaction dated Tuesday, February 25th. The shares were sold at an average price of $58.05, for a total transaction of $580,500.00. Following the completion of the sale, the senior vice president now owns 185,453 shares of the company's stock, valued at $10,765,546.65. This trade represents a 5.12 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 31,697 shares of company stock worth $1,754,451. Company insiders own 2.40% of the company's stock.

Analyst Ratings Changes

A number of research analysts recently commented on the stock. Wells Fargo & Company dropped their target price on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating on the stock in a research report on Monday, January 13th. HC Wainwright reaffirmed a "buy" rating on shares of Halozyme Therapeutics in a research report on Thursday, March 6th. Benchmark reaffirmed a "buy" rating and issued a $75.00 target price on shares of Halozyme Therapeutics in a research report on Thursday, February 20th. Finally, Piper Sandler raised their price objective on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a "neutral" rating in a research report on Friday, January 10th. Four research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, Halozyme Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $62.78.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.